HPV 16 Infection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Papivax
PapivaxTaiwan - Taipei
1 program
1
pNGVL4a-Sig/E7Phase 11 trial
Active Trials
NCT06508138Enrolling By InvitationEst. Oct 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
PapivaxpNGVL4a-Sig/E7

Clinical Trials (1)

NCT06508138PapivaxpNGVL4a-Sig/E7

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

Start: Oct 2023Est. completion: Oct 2027
Phase 1Enrolling By Invitation

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space